Is it safe to administer digoxin (digitalis glycoside) in patients with liver failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Digoxin can be safely administered in patients with liver failure, but caution is warranted. The primary elimination route for digoxin is renal excretion, with only about 10-20% of the drug metabolized by the liver 1. Therefore, liver dysfunction alone typically does not significantly alter digoxin clearance or require substantial dose adjustments. However, patients with advanced liver disease often develop concurrent kidney dysfunction, which would necessitate dose reduction. Additionally, these patients may have altered volume of distribution, electrolyte abnormalities (particularly hypokalemia, hypomagnesemia, and hypercalcemia), and may be taking multiple medications that could interact with digoxin.

When administering digoxin to patients with liver failure, start with standard loading doses if needed (0.5-1 mg over 24 hours, divided), but consider reducing maintenance doses (typically 0.125-0.25 mg daily) and monitor digoxin levels closely, aiming for therapeutic concentrations of 0.8-2.0 ng/mL. Regular monitoring of renal function, electrolytes, and clinical response is essential to prevent toxicity, which can manifest as nausea, visual disturbances, cardiac arrhythmias, and other symptoms. It is also important to note that hypokalemia can increase the risk of digoxin toxicity, even at low serum digoxin levels 2.

Some key points to consider when using digoxin in patients with liver failure include:

  • Monitoring serum digoxin levels and adjusting the dose as needed
  • Regularly assessing renal function and electrolyte levels
  • Being aware of potential interactions with other medications
  • Starting with a low dose and gradually increasing as needed and tolerated
  • Monitoring for signs of toxicity, such as nausea, visual disturbances, and cardiac arrhythmias.

It's worth noting that the most recent study 3 suggests that digoxin may be a therapeutic option for rate and symptom control for some patients with cardiac amyloidosis, but rigorous patient selection is recommended, and patients should be closely monitored during digoxin administration. However, this study does not specifically address the use of digoxin in patients with liver failure.

In general, the use of digoxin in patients with liver failure should be individualized and based on the patient's specific clinical needs and circumstances. The goal is to balance the potential benefits of digoxin therapy with the risks of toxicity and other adverse effects.

References

Research

Digoxin remains useful in the management of chronic heart failure.

The Medical clinics of North America, 2003

Research

Digoxin Use in Cardiac Amyloidosis.

The American journal of cardiology, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.